Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

BlueRock Therapeutics

- PMLiVE

AbbVie submits Parkinson’s disease therapy to FDA

The therapy offers a first-of-its-kind, 24-hour, continuous subcutaneous delivery

- PMLiVE

The Michael J Fox Foundation gives Asceneuron second research grant

Parkinson's disease affects an estimated seven to ten million people worldwide

- PMLiVE

AbbVie ends partnership with BioArctic to develop treatment for Parkinson’s disease

Results supporting phase 2 trials were presented at the International Congress of Parkinson’s Disease and Movement Disorders in September 2021

- PMLiVE

Parkinson’s UK and Domainex announce new collaboration

Parkinson’s Virtual Biotech plans to invest up to £3m in the project

- PMLiVE

SMC approves Parkinson’s disease treatment Ongentys

The once-daily additional oral treatment for patients living with Parkinson’s disease is now accepted for use within NHS Scotland

Lesson Learned from the Pandemic

Tom Hsu, VP of Specialty Medicine at Bayer Canada, talks about how he got to where he is today and his experience working for Bayer in China and how that...

Impetus Digital

- PMLiVE

Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease

Researchers identified eight Parkinson’s disease states, with seven outcomes associated with terminal Parkinson’s disease

- PMLiVE

CHMP rejects Kyowa Kirin’s Parkinson’s disease drug

Results of eight main studies of drug were 'inconsistent', according to the CHMP

Bayer symbol

Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy

In 2019, Bayer bought out its private equity partner Versant Ventures and founders in BlueRock Therapeutics for $240m

- PMLiVE

Anavex’s CNS drug slows progression of motor and non-motor symptoms in Parkinson’s disease

Clinical benefit correlated with increase in target biomarker SIGMAR1

- PMLiVE

Servier, Oncodesign select first preclinical candidate from Parkinson’s disease collaboration

Oncodesign received the first milestone payment in February 2020 as part of the collaboration

- PMLiVE

Annovis Bio’s lead therapeutic shows ‘significant improvements’ in Alzheimer’s, Parkinson’s

Patients from a small phase 2a study saw their ADAS-Cog11 scores improve by 4.4 points

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links